Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Monday session in green amid volatile trading. The shares closed up +0.64 points or 2.43% at $26.97 with 13.22 million shares getting traded. Post opening the session at $26.31, the shares hit an intraday low of $26.15 and an intraday high of $27.07 and the price vacillated in this range throughout the day. The company has a market cap of $8.97 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 aleant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016 .
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa , Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”
Shares of Pfizer Inc. (NYSE:PFE) ended Monday session in green amid volatile trading. The shares closed up +0.48 points or 1.42% at $34.28 with 15.56 million shares getting traded. Post opening the session at $33.90, the shares hit an intraday low of $33.74 and an intraday high of $34.33 and the price vacillated in this range throughout the day. The company has a market cap of $208.92 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2016 Performance Report, to be issued that morning.
To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quarterly Corporate Performance – Third Quarter 2016” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning now. Participants are advised to pre-register in advance of the conference call.
You can also listen to the conference call by dialing either (866) 662-3198 in the United States and Canada or (484) 747-6805 outside of the United States and Canada. The password is “Third Quarter Earnings”.
Visitors to www.pfizer.com will be able to view and listen to an archived copy of the webcast of the conference call.